Henry T. Lynch

Phase II breast cancer chemoprevention trial of the third generation selective estrogen receptor modulator arzoxifene.

M. Mayo, C. Zalles, B. Kimler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

O. Olopade, T. Rebbeck, R. Eeles, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers

F. Couch, O. Olopade, T. Rebbeck, 2010, Breast Cancer Research and Treatment.